Stratrix
Company data sheet · Amgen

Amgen: profitable every year.

Industry
Biological Products,
Headquarters
United States
Ticker
AMGN (Nasdaq)
Sources
SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
Data as of
November 2, 2026
  1. One decision on record. Stratrix has verified one of Amgen's big decisions, each with what happened next.
  2. Profitable every year. Amgen made money in each of its last ten fiscal years, from $2 billion (2017) to $8.4 billion (2018).

Financial results

Fiscal yearRevenueNet income
2016$23 billion$7.7 billion
2017$22.8 billion$2 billion
2018$23.7 billion$8.4 billion
2019$23.4 billion$7.8 billion
2020$25.4 billion$7.3 billion
2021$26 billion$5.9 billion
2022$26.3 billion$6.6 billion
2023$28.2 billion$6.7 billion
2024$33.4 billion$4.1 billion
2025$36.8 billion$7.7 billion

As reported in its annual filings. Losses in red.

Stratrix Decision Cases

Has Amgen had layoffs?

Job cuts, severance and restructuring

  1. Company ran a restructuring plan that was started and substantially finished in 2023, with related expenses recorded in other operating expenses. 2023

    “Other operating expenses for 2023 primarily consisted of a net IPR&D intangible asset impairment charge for AMG 340 and expenses related to our restructuring plan that were both initiated and substantially completed in 2023.” 10-K for 2024
  2. Company incurred expenses tied to cost-savings initiatives in 2024, recorded in other operating expenses. 2024

    “Other operating expenses for 2024 primarily consisted of impairment charges associated with IPR&D intangible assets related to our Teneobio acquisition in 2021 and expenses related to cost-savings initiatives incurred in 2024.” 10-K for 2024
  3. Company recorded acquisition costs for the Horizon closing, including severance and other employee-related expenses. three months ended December 31, 2023 · Cost: approximately $ 487 million

    “During the three months ended December 31, 2023, the Company incurred approximately $ 487 million of acquisition costs related to the closing of our Horizon acquisition, consisting of $ 167 million for share-based payments to settle non-vested equity awards attributable to post-combination services, severance and other employee-related expenses and $ 320 million for transaction costs.” 10-K for 2024
  4. Amgen reported expenses for cost-savings initiatives in 2024 and for a restructuring plan that was started and substantially completed in 2023, both included in other operating expenses. 2023

    “Other operating expenses for 2023 included a net IPR&D intangible asset impairment charge for AMG 340 and expenses related to our restructuring plan that were both initiated and substantially completed in 2023.” 10-K for 2025
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedRestructuring chargesCash paid for restructuring
2016-12-31$19 million$117 million
2017-12-31$79 million$31 million
2023-12-31$267 million—

Amgen has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.

What has Amgen acquired?

Deals its annual reports describe

BusinessDealWhenValue
Horizon Therapeutics plc
“In October 2023, we completed our acquisition of Horizon for $116.50 per share in cash, representing a total transaction price of $27.8 billion.” 10-K for 2023
acquisitionIn October 2023$116.50 per share in cash, representing a total transaction price of $27.8 billion
Bergamo subsidiary
“(2) Consists of product sales of our non-principal products, as well as sales prior to the divestiture of our Bergamo and Gensenta subsidiaries in the second quarter of 2023 and fourth quarter of 2022, respectively.” 10-K for 2023
divestituresecond quarter of 2023—
Gensenta subsidiary
“(2) Consists of product sales of our non-principal products, as well as sales prior to the divestiture of our Bergamo and Gensenta subsidiaries in the second quarter of 2023 and fourth quarter of 2022, respectively.” 10-K for 2023
divestiturefourth quarter of 2022—
ChemoCentryx
“Cash used in investing activities during 2022 was primarily due to our $3.8 billion purchase of ChemoCentryx and net cash outflows related to marketable securities of $1.4 billion.” 10-K for 2023
acquisition—$3.8 billion purchase of ChemoCentryx
Teneobio and Five Prime
“Cash provided by investing activities during 2021 was primarily due to net cash inflows related to marketable securities of $4.3 billion, partially offset by cash used in the acquisitions of Teneobio and Five Prime of $2.5 billion.” 10-K for 2023
acquisition2021$2.5 billion
Otezla (acquired from Bristol Myers Squibb Company)
“Otezla was acquired from Bristol Myers Squibb Company in November 2019 after their acquisition of Celgene.” 10-K for 2023
acquisitionNovember 2019—
Otezla (from Bristol-Myers Squibb Company)
“Otezla was acquired from Bristol-Myers Squibb Company in November 2019 after its acquisition of Celgene Corporation.” 10-K for 2024
acquisitionNovember 2019—
BeiGene, Ltd.
“In January 2020, we acquired an equity stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China.” 10-K for 2024
acquisitionJanuary 2020approximately $2.8 billion in cash
Gensenta
“Other operating expenses for 2022 primarily consisted of a loss on the divestiture of Gensenta.” 10-K for 2024
divestiture——
Horizon
“(1) TEPEZZA and KRYSTEXXA were acquired from our Horizon acquisition on October 6, 2023, and include product sales in the periods after the acquisition date.” 10-K for 2025
acquisitionOctober 6, 2023—
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-12-31$0$0
2017-12-31$19 million$0
2018-12-31−$195 million$6 million
2019-12-31$13.62 billion$26 million
2020-12-31$0$0
2021-12-31$2.53 billion$251 million
2022-12-31$3.84 billion$651 million
2023-12-31$26.99 billion—
2024-12-31$0—
2025-12-31$53 million—

Deal filings since 2016

Who are Amgen's competitors?

Who Amgen names

CompanyNamed in
Novartis AG2025
Regeneron Pharmaceuticals, Inc.2025

In its own words

  1. Novartis AG, Regeneron Pharmaceuticals, Inc.

    “Product Territory Competitor-marketed product Competitors Prolia U.S., Europe & Asia Pacific Bisphosphonates, including generics Various U.S., Europe & Asia Pacific Denosumab biosimilars Various Repatha U.S., Europe & Asia Pacific LEQVIO ® Novartis AG U.S., Europe & Asia Pacific PRALUENT ® Regeneron Pharmaceuticals, Inc.” 10-K for 2025

Who names Amgen

Companies whose own annual reports name Amgen as a competitor.

  1. Endo names it as “Amgen, Inc.” · 2024

    “This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2024
  2. Endo International names it as “Amgen, Inc.” · 2023

    “This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2023
  3. Jazz Pharmaceuticals names it as “Amgen Inc.” · 2025

    “There are also a number of products for the treatment of first and second line SCLC in various phases of development, including Amgen Inc.’s tarlatamab, which was approved for second line use in the U.S. in May 2024.” 10-K for 2025

What are Amgen's subsidiaries?

Subsidiaries it lists

SubsidiaryJurisdiction
Amgen (Europe) GmbHSwitzerland
Amgen Canada Inc.Canada
Amgen Fremont Inc.Delaware
Amgen Global Finance B.V.Netherlands
Amgen Global Technology Unlimited CompanyIreland
Amgen GmbH GermanyGermany
Amgen Ilaç Ticaret Limited ŞirketiTürkiye
Amgen International Holdings Inc.Delaware
Amgen K.K.Japan
Amgen K-A, Inc.Delaware
Amgen Manufacturing Limited LLCPuerto Rico
Amgen Rare Disease Holdings Inc.Delaware
Amgen Research (Munich) GmbHGermany
Amgen S.A.S.France
Amgen S.p.A.Italy
Amgen SF, LLCDelaware
Amgen Singapore Holding Pte. Ltd.Singapore
Amgen Singapore Manufacturing Pte. Ltd.Singapore
Amgen Technology (Ireland) Unlimited CompanyIreland
Amgen Technology, LimitedBermuda
Amgen USA Inc.Delaware
Amgen Worldwide Holdings B.V.Netherlands
Amgen, S.A.Spain
BioVex LLCDelaware
ChemoCentryx, Inc.Delaware
Five Prime Therapeutics, Inc.Delaware
Horizon Therapeutics Finance S.à.r.lLuxembourg
Horizon Therapeutics Holdings LimitedIreland
Horizon Therapeutics Ireland DACIreland
Horizon Therapeutics LimitedIreland
Horizon Therapeutics Services LLCDelaware
Horizon Therapeutics U.S. Holding LLCDelaware
Horizon Therapeutics USA, Inc.Delaware
HZNP Finance LimitedBermuda
Immunex CorporationWashington
Immunex Rhode Island CorporationDelaware
Onyx Pharmaceuticals, Inc.Delaware
Onyx Therapeutics, Inc.Delaware
Pillartree LimitedIreland
Saga Investments Coöperatief U.A.Netherlands
TeneoBio, Inc.Delaware
Viela Bio, Inc.Delaware

From Exhibit 21 of the 10-K for 2025. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.

Layoffs, acquisitions, competitors and subsidiaries are read from Amgen’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-13.

The full data sheet · Data Plan

Everything behind these findings, ready for your board deck.

  • Market reaction to disclosed decisions: 55 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (19 with market data).
  • Economic context: 7 measures for the United States, every year since 2016, from the official sources.
  • Peer comparison: against 264 companies of its size in its sector.
  • Financial results: ten years of revenue, operating and net income, and every annual report, linked.
  • Methods and sources, so each number can be checked and cited.

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Stratrix Team

Every Casebook, three Strategy Packs a seat each year and Ask Stratrix, for teams that face these decisions all year.

$1,999 a year · $499 a seatWhat is included →

New analyses, by email

The defining moves in business, and what they teach, as they publish.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.